Brokerages Set Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) PT at $23.87

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have received a consensus recommendation of “Hold” from the ten brokerages that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $24.17.

Several research analysts recently commented on DCPH shares. Jonestrading reissued a “hold” rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a research note on Monday. Jefferies Financial Group restated a “hold” rating and set a $25.60 target price (down from $26.00) on shares of Deciphera Pharmaceuticals in a research note on Monday. Barclays upgraded shares of Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and lifted their price target for the stock from $9.00 to $26.00 in a research note on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Wednesday, March 20th. Finally, Guggenheim reiterated a “neutral” rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday.

Deciphera Pharmaceuticals Stock Performance

NASDAQ DCPH opened at $25.36 on Monday. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -11.07 and a beta of 0.39. The firm has a 50 day simple moving average of $16.18 and a 200-day simple moving average of $14.63. Deciphera Pharmaceuticals has a one year low of $9.90 and a one year high of $25.40.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The company had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. During the same quarter last year, the company posted ($0.60) EPS. The firm’s revenue was up 32.9% compared to the same quarter last year. Equities analysts predict that Deciphera Pharmaceuticals will post -2.16 EPS for the current fiscal year.

Institutional Trading of Deciphera Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Diversified Trust Co lifted its holdings in shares of Deciphera Pharmaceuticals by 6.5% in the 1st quarter. Diversified Trust Co now owns 12,747 shares of the company’s stock valued at $201,000 after purchasing an additional 778 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Deciphera Pharmaceuticals by 96.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after buying an additional 997 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Deciphera Pharmaceuticals by 2.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 41,527 shares of the company’s stock valued at $670,000 after buying an additional 1,117 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Deciphera Pharmaceuticals by 10.3% in the third quarter. Principal Financial Group Inc. now owns 18,266 shares of the company’s stock valued at $232,000 after acquiring an additional 1,699 shares during the period. Finally, Quest Partners LLC purchased a new position in shares of Deciphera Pharmaceuticals during the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 70.96% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.